43.37
+2.42(+5.91%)
Currency In USD
| Previous Close | 40.95 |
| Open | 42.49 |
| Day High | 43.45 |
| Day Low | 41.55 |
| 52-Week High | 44.65 |
| 52-Week Low | 25.28 |
| Volume | 2.12M |
| Average Volume | 2.07M |
| Market Cap | 6.64B |
| PE | 15.16 |
| EPS | 2.86 |
| Moving Average 50 Days | 37.17 |
| Moving Average 200 Days | 32.84 |
| Change | 2.42 |
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
GlobeNewswire Inc.
Mar 09, 2026 11:30 AM GMT
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people wit
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
GlobeNewswire Inc.
Mar 06, 2026 12:30 PM GMT
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ETNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET t